Cost-effectiveness of Qiliqiangxin in HFrEF: adjunctive therapy vs. standard care from a Chinese healthcare perspective
QLQX capsules, as adjunctive therapy to standard treatment, represent a cost-effective strategy for managing HFrEF in China, supporting their inclusion in clinical guidelines and reimbursement policies. Real-world studies are needed to validate these results further.
Authors
- Yake Lou (ORCID: https://orcid.org/0000-0002-2632-4412)
- Huadong Zheng (ORCID: https://orcid.org/0000-0003-0587-9889)
- Xue Xiang
- Xiuli Li (ORCID: https://orcid.org/0009-0006-2327-0531)
- Yetong Wu
Institutions
- Capital Medical University (CN)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Beijing Anzhen Hospital (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- BMC Complementary Medicine and Therapies
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1186/s12906-025-05181-6
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00